Dtsch Med Wochenschr 2011; 136(49): 2560-2561
DOI: 10.1055/s-0031-1292831
Kommentar | Commentary
Leitlinien
© Georg Thieme Verlag KG Stuttgart · New York

Wer schützt Ärzte und Patienten vor Leitlinien?

Who protects physicians and patients from guidelines?
M. Wehling
Further Information

Publication History

19 October 2011

28 October 2011

Publication Date:
30 November 2011 (online)

 
  • Literatur

  • 1 European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
  • 2 European Medicines Agency (EMA). European Medicines Agency recommends restricting use of Multaq. http://www.ifap.de Letzter Zugriff: 9.11.2011
  • 3 Philippin Y. Multaq: vers la fin du remboursement. http://www.liberation.fr Letzter Zugriff: 9.11.2011
  • 4 Sanofi Aventis. Sanofi provides Multaq® Phase IIIb PALLAS Trial update. http://en.sanofi.com Letzter Zugriff: 9.11.2011
  • 5 Serebruany VL.. Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?. Cardiology 2010; 117: 280-283
  • 6 Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555